Analytical Data
-
Gene name
CDK6
- Application
-
Alternative Names
PLSTIRE; Cell division protein kinase 6; Serine/threonine-protein kinase PLSTIRE
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
Q00534
-
Expression Region
Met1~Ala326
-
Molecular Weight
41kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Cyclin-dependent kinase 6 (CDK6) is a critical serine/threonine kinase that plays a vital role in regulating the cell cycle, particularly in transitioning from the G1 phase to the S phase. Its activity is tightly regulated by cyclins and CDK inhibitors, making it an important target for cancer research, especially in tumors with dysregulated cell cycle progression. Overexpression or constant activation of CDK6 has been implicated in various malignancies, including leukemia, breast cancer, and glioblastoma, where it contributes to uncontrolled cellular proliferation. Recent studies have highlighted the potential of CDK6 as a therapeutic target, leading to the development of selective CDK6 inhibitors that can effectively hinder tumor growth while sparing normal cells. The study of recombinant CDK6 proteins provides valuable insights into its structure, function, and interaction with other cellular proteins, facilitating the identification of novel inhibitors and advancing our understanding of CDK6's role in oncogenesis. Through structural biology techniques and biophysical analyses, researchers aim to delineate the molecular mechanisms by which CDK6 contributes to cancer and to explore potential therapeutic strategies aimed at modulating its activity. As our understanding of CDK6 evolves, the development of precise and effective treatment options based on CDK6 modulation holds promise for improving cancer therapeutics and patient outcomes.
